Harmony Biosciences Holdings Inc.’s recently made public that its Director Wicki Andreas unloaded Company’s shares for reported $9.29 million on Nov 04. In the deal valued at $58.81 per share,157,950 shares were sold. As a result of this transaction, Wicki Andreas now holds 2,435,323 shares worth roughly $ 143.32 million.
Do You Own These 7 Inflation-Survival Stocks?
Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.
Click here to get your free copy of the report
Then, Dayno Jeffrey M. sold 15,000 shares, generating $900,332 in total proceeds. Upon selling the shares at $60.02, the CHIEF MEDICAL OFFICER now owns 0 shares.
Before that, Wicki Andreas sold 254,141 shares. Harmony Biosciences Holdings Inc. shares valued at $15,106,141 were divested by the Director at a price of $59.44 per share. As a result of the transaction, Wicki Andreas now holds 2,593,273 shares, worth roughly $152.61 million.
Jefferies upgraded its Harmony Biosciences Holdings Inc. [HRMY] rating to a Buy from a a Hold in a research note published on Friday, October 14, 2022; the price target was increased to $61 from $57. PT values the company’s stock at a premium of 3.52 to its Friday closing price. A number of analysts have revised their coverage, including Janney’s analysts, who increased its forecast for the stock in mid October from “a Neutral” to “a Buy”. Jefferies also remained covering HRMY and has decreased its forecast on August 03, 2022 with a “Hold” recommendation from previously “Buy” rating. Goldman revised its rating on July 13, 2022. It rated HRMY as “a Neutral” which previously was an “a Buy”.
Price Performance Review of HRMY
On Friday, Harmony Biosciences Holdings Inc. [NASDAQ:HRMY] saw its stock fall -1.82% to $58.85. On the same session, the stock had its day’s lowest price of $57.23, but rose to a high of $60.66. Over the last five days, the stock has gained 12.35%. Harmony Biosciences Holdings Inc. shares have risen nearly 38.02% since the year began. Nevertheless, the stocks have risen 38.47% over the past one year. While a 52-week high of $60.62 was reached on 11/04/22, a 52-week low of $31.54 was recorded on 01/24/22. SMA at 50 days reached $47.78, while 200 days put it at $46.10. A total of 0.72 million shares were traded, compared to the trading of 0.94 million shares in the previous session.
Levels Of Support And Resistance For HRMY Stock
The 24-hour chart illustrates a support level at 57.17, which if violated will result in even more drops to 55.48. On the upside, there is a resistance level at 60.60. A further resistance level may holdings at 62.34. The Relative Strength Index (RSI) on the 14-day chart is 71.35, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 5.68, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 14.11%. Stochastics %K at 89.89% indicates the stock is a selling.
How much short interest is there in Harmony Biosciences Holdings Inc.?
A steep rise in short interest was recorded in Harmony Biosciences Holdings Inc. stocks on Jul 14, 2022, growing by 0.55 million shares to a total of 4.68 million shares. Yahoo Finance data shows the prior-month short interest on Jun 14, 2022 was 4.13 million shares. There was a rise of 11.75%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 16.44% of the overall stock float, the days-to-cover ratio (short ratio) rose to 8.65.
Harmony Biosciences Holdings Inc. [HRMY] – Who Are The Largest Shareholders?
In filings from Fidelity Management & Research Co, it is revealed that the company now owns 5,426,597 shares, or roughly 9.17% of the outstanding HRMY shares. In other words, the investor’s shares have risen by 529,593 from its previous 13-F filing of 4897004.0. Additionally, BlackRock Fund Advisors increased 5.32% of its stake after which the total value it holdings stand at $156,310,040, while HBM Partners AG reduced -16.11% of its stake to hold $133.41 million in the firm. Over the last quarter, The Vanguard Group, Inc. purchased 256,158 shares of Harmony Biosciences Holdings Inc., while Janus Henderson Investors US LLC bought -179,741 shares. At present, Adage Capital Management LP is holding 1,034,450 shares valued at $45.82 million. SSgA Funds Management, Inc. owned 944,335 shares of the company at the time of its most recent 13F filing, worth $41.82 million.
According to FactSet, Harmony Biosciences Holdings Inc.’s share price will average $63.63 in the next year, based on opinions of analysts polled by the firm. This is up nearly 5.94 percent from its previous closing price of $59.94. Analysts expect Harmony Biosciences Holdings Inc. stock to reach the higher price of $71.00, while the lowest price estimate is $52.00. However, 8 analysts have rated HRMY stock as a Buy in their predictions for 2022. The most recent change occurred on July 07, 2022 when Mizuho began covering the stock and recommended ‘”a Buy”‘ rating along with a $64 price target.